Bisphosphonates

European Journal of Cancer

Volumn 34, Issue 2, 1998, Pages 263-269

  Body, J J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; DOSE RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0032512896     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10136-8     Document Type: Article

References (45)

1. 2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982, 70, 927-933.
2. 2. Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88, 2095-2105.
3. 3. Zimolo Z, Wesolowski G, Rodan GA. Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest 1995, 96, 2277-2283.
4. 4. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996, 137, 2324-2333.
5. 5. Body J-J, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcaemia. J Clin Endocrinol Metab 1992, 74, 471-475.
6. 6. Stewart AF, Vignery A, Silverglate A, et al. Quantitative bone histomorphometry in humoral hypercalcaemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab 1982, 55, 219-227.
7. 7. Grill V, Ho P, Body J-J, et al. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 1991, 73, 1309-1315.
8. 8. Burtis WJ. Parathyroid hormone-related protein: structure, function and measurement. Clin Chem 1992, 38, 2171-2183.
9. 9. Body J-J. Bone metastases and tumor-induced hypercalcemia. Current Opin Oncol 1992, 4, 624-631.
10. 10. Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. Arch Intern Med 1991, 151, 471-476.
11. 11. O'Rourke NP, McCloskey EV, Vasikaran S, Eyres K, Fern D, Kanis JA. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993, 67, 560-563.
12. 12. Body J-J, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev 1996, 22, 265-287.
13. 13. Harinck HIJ, Bijvoet OLM, Plantingh AST, et al. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 1987, 82, 1133-1142.
14. 14. Thiébaud D, Jaeger J, Jacquet AF, Burckhardt P. Dose response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrPB. J Clin Oncol 1988, 6, 762-768.
15. 15. Body J-J, Dumon JC. Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: dose response relationship and influence of the tumour type. Ann Oncol 1994, 5, 359-363.
16. 16. Wall J, Ratdiffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994, 70, 169-172.
17. 17. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995, 72, 1289-1293.
18. 18. Vinholes J-J, Guo C-Y, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomised comparison of pamidronate or clodronate for hypercalcaemia of malignancy. J Clin Oncol 1996, 15, 131-138.
19. 19. Body J-J, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997, 75, 408-412.
20. 20. Guise TA, Mundy GR. Breast cancer and bone. Curr Opin Endo 1995, 2, 548-555.
21. 21. Siwek B, Lacroix M, de Pollak C, Marie P, Body J-J. Secretory products of breast cancer cells affect human osteoblastic cells: partial characterization of active factors. J Bone Miner Res 1997, 12, 552-560.
22. 22. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995, 13, 2427-2430.
23. 23. Ernst DS, MacDonald RN, Paterson AHG, Jensen J, Bruera E. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Mngmt 1992, 7, 4-11.
24. 24. Vinholes JF, Purohit OP, Abbey M, Eastell R, Coleman RE. Relationship between biocemid and symtomtic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol, 8, 1243-1253.
25. 25. Purohit OP, Anthony C, Radstone CR, Owen J, Coleman RE. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1996, 70, 554-558.
26. 26. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996, 335, 1785-1791.
27. 27. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 59-65.
28. 28. Van Hoten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 491-498.
29. 29. Conte PF, Latreille J, Mauriac L, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. J Clin Oncol 1996, 14, 2552-2559.
30. R) infusions. Proceedings of ASCO 1997, 16, 152 (Abstr. 531).
31. 31. Richards MA, Braysher S, Gregory WM, Rubens RD. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993, 67, 856-860.
32. 32. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone 1991, 12 (Suppl. 1), 37-42.
33. 33. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995, 55, 3551-3557.
34. 34. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19, 663-667.
35. 35. Knoop AS, Laenkholm AV, Mirza MR, Hansen S, Thorpe SM, Rose C. Prognostic and predictive factors in early breast cancer. Educational Book, 19th ESMO Congress 1994, 9-18.
36. 36. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992, 40, 1049-1052.
37. 37. Laakso M, Lahtinen R, Virkkunen P, Elomaa I, for the Finnish Leukaemia Group. Subgroup and cost-benefit analysis of the Finnish mulitcentre trial of clodronate in multiple myeloma. Br J Haematol 1994, 87, 725-729.
38. 38. McCloskey EV, Maclennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. Effect of clodronate on progression of skeletal disease in multiple myelomatosis. Eur J Cancer 1995, 31A (Suppl. 5), S162(Abstract).
39. 39. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334, 488-493.
40. 40. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991, 6, 1003-1011.
41. 41. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994, 9, 745-750.
42. 42. Pecherstorfer M, Herrmann Z, Body J-J, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14, 268-276.
43. 43. Ralston SH, Thiébaud D, Herrmann Z, et al. Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br J Cancer 1997, 75, 295-300.
44. 44. Body J-J. Clinical research update: zoledronate. Cancer 1997, 80, 1169-1701.
45. 45. Pecherstorfer M, Ludwig H, Schlosser K, Buck S, Huss HJ, Body J-J. Administration of the bisphosphonate ibandronate (BM 21.0955) by a intravenous bolus injection. J Bone Miner Res 1996, 11, 587-593.